Open Access Highly Accessed Review

Exogenous endothelial cells as accelerators of hematopoietic reconstitution

J Christopher Mizer1, Thomas E Ichim12*, Doru T Alexandrescu1, Constantin A Dasanu3, Famela Ramos1, Andrew Turner4, Erik J Woods5, Vladimir Bogin12, Michael P Murphy6, David Koos1 and Amit N Patel7

Author Affiliations

1 Regen BioPharma Inc, San Diego, CA, USA

2 Medistem Inc, San Diego, CA, USA

3 University of Connecticut School of Medicine, Hartford, CT, USA

4 University of Washington, Seattle, WA, USA

5 Cook General Biotechnology LLC, Indianapolis, IN, USA

6 Indiana University, Indianapolis, IN, USA

7 University of Utah, Salt Lake City, UT, USA

For all author emails, please log on.

Journal of Translational Medicine 2012, 10:231  doi:10.1186/1479-5876-10-231

Published: 21 November 2012

Abstract

Despite the successes of recombinant hematopoietic-stimulatory factors at accelerating bone marrow reconstitution and shortening the neutropenic period post-transplantation, significant challenges remain such as cost, inability to reconstitute thrombocytic lineages, and lack of efficacy in conditions such as aplastic anemia. A possible means of accelerating hematopoietic reconstitution would be administration of cells capable of secreting hematopoietic growth factors. Advantages of this approach would include: a) ability to regulate secretion of cytokines based on biological need; b) long term, localized production of growth factors, alleviating need for systemic administration of factors that possess unintended adverse effects; and c) potential to actively repair the hematopoietic stem cell niche. Here we overview the field of hematopoietic growth factors, discuss previous experiences with mesenchymal stem cells (MSC) in accelerating hematopoiesis, and conclude by putting forth the rationale of utilizing exogenous endothelial cells as a novel cellular therapy for acceleration of hematopoietic recovery.